.svg){kind=small}
RetinAI & OptymEdge Collaborate to Accelerate Ophthalmic Drug Development Through AI-Powered Reading Center Solutions
This collaboration focuses on exploring the integration of RetinAI Discovery® and advanced AI capabilities with OptymEdge’s Reading center to optimize clinical trial workflows and accelerate time-to-market for new therapies.
BERN, Switzerland and ROCKVILLE, Maryland - Ikerian AG (parent company of RetinAI US Inc.) and OptymEdge, part of the Emmes Group, are pleased to announce a new collaboration to accelerate clinical development pipelines. This initiative aims to optimize clinical trials workflows by integrating RetinAI Discovery® platform and advanced AI analysis capabilities with OptymEdge’s next-generation reading center offering supported by its proprietary Acuvera platform.
The collaboration seeks to streamline the imaging workflow for ophthalmic clinical trials by combining high-speed, centralized data and image management with automated biomarker detection. By leveraging RetinAI’s industry-leading AI tools with OptymEdge’s reading center operations and clinical trial infrastructure, the two companies intend to deliver sponsors faster, more consistent and scalable imaging analysis across Retina, and broader ophthalmology studies.
"Integrating advanced analytics and AI into the foundational layer of Reading Center services is no longer just an advantage, it is a necessity for the future of clinical trials," said Carlos Ciller, CEO and Co-founder at RetinAI. "Collaborating with OptymEdge allows us to explore how our joint offering can deliver unparalleled value to clinical research."
"Our mission is to ensure the highest level of endpoint integrity for ophthalmic clinical trials," said Ana Rita Santos, Head of Scientific Affairs & Imaging at OptymEdge. "By exploring the integration of the RetinAI Discovery® platform and its AI-driven advanced analytics with our Acuvera Platform, we are creating a more agile, digital Reading Center. This collaboration is designed to optimize clinical workflows and accelerate the drug development lifecycle, providing sponsors with the high-quality, automated insights needed to bring life-changing ophthalmic therapies to market more efficiently."
”The future of reading centers lies in intelligent, integrated platforms, said Saqib Parkar, CEO at OptymEdge. Through this collaboration, we are embedding AI directly into the clinical workflow—unlocking more consistent, scalable, and data-rich imaging endpoints for ophthalmology trials. These are very exciting times.”
Media Contact
Email: media@retinai.com I Website: www.retinai.com
About Ikerian & RetinAI
Established in 2017, Ikerian AG (formerly RetinAI Medical AG) and its subsidiary, RetinAI U.S. Inc. (‘Ikerian’, ‘RetinAI’ and, together, ‘the company’), develops software solutions to accelerate clinical, research and pharmaceutical workflows globally using advanced machine learning and computer vision. Focused on the ophthalmology and optometry market, RetinAI builds tools to collect, organize and analyze health data from the eyes, enabling healthcare professionals to make the right decisions sooner in healthcare. RetinAI's international team leverages its clinical, technical, and scientific expertise to foster the transition from reactive to preventive medicine for severe eye diseases. A commercial stage company with growing sales from RetinAI Discovery®, RetinAI has established collaborations and partnerships with leading ophthalmology clinical networks and pharmaceutical companies. About Ikerian AG www.ikerian.com and RetinAI Inc. US www.retinai.com.
About Optymedge
OptymEdge is a global partner in ophthalmic clinical trials, with over 30 years of experience supporting visual function endpoints and certification. The company works with more than 2,500 sites across 120+ active studies and partners with leading CROs and pharmaceutical sponsors.
Through the Acuvera platform suite, OptymEdge is expanding its capabilities in imaging and reading services—bringing together standardized processes, quality control, and AI-supported analysis to deliver scalable, regulatory-ready data.
